GlassScriptPhysician profile
Prakul Chandra
NPI 1497911937
$1,883.67
in general payments reported to CMS, 2019-2025
23 companies · $547 in 2025
The $547 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.22 · 2020: $192 · 2021: $340 · 2022: $345 · 2023: $156 · 2024: $260 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $713.84 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $219.65 | 2022-2025 | Rexulti |
| Abbvie INC. | $124.11 | 2021-2024 | Vraylar |
| Philips North America LLC | $96.06 | 2025 | Ambulatory Monitoring & Diagnostics Undivided, Ecc Solutions |
| Pfizer INC. | $93.14 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $81.43 | 2019-2020 | |
| Exact Sciences Corporation | $70.28 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $61.47 | 2023-2024 | Mounjaro |
| Amgen INC. | $51.51 | 2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $41.95 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $38.82 | 2024-2025 | Airsupra |
| Athena Bioscience, LLC | $38.67 | 2022-2025 | Qdolo, Nexiclon Xr |
| Eisai INC. | $36.46 | 2020-2021 | |
| Biogen, INC. | $34.69 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.06 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.11 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.95 | 2025 | Caplyta |
| Allergan, INC. | $22.93 | 2020 | |
| Sunovion Pharmaceuticals INC. | $19.49 | 2021 | |
| Dexcom, INC. | $17.89 | 2023 | Dexcom G6 Transmitter |
| Lundbeck LLC | $16.86 | 2023 | Rexulti |
| Abbott Laboratories | $15.31 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prakul Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.